NCT07564414ClinicalTrials.gov

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity With or Without Type 2 Diabetes

RecruitingTaking participants now, according to the registry record.

Contact this study

In brief

Phase 32,500 participants sought303 sites19 countries

Registered in 1 registry

ClinicalTrials.govNCT07564414Open this record at ClinicalTrials.govSynced 3 weeks ago

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2026-05-04; recorded start 2026-05-21
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Present: Participants are randomly assignedAllocation is recorded as randomised
Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
Present: Uses blinding (masking)A masking level is recorded in the record
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Present: Sponsor has 333 other studies in this databaseCounted from the lead sponsor named in the record (Novo Nordisk A/S)
Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database

The record lists 2 conditions.
Lead sponsor type recorded as: industry.
Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation20/20
Participants are randomly allocated between arms
Blinding20/20
Quadruple-blind
Control arm15/15
Active-comparator control arm
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
Multi-centre8/8
Multi-centre: 303 sites
Data monitoring committee0/7
No data monitoring committee stated
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,500 participants (target), run at 303 sites, across 19 countries.

How this score is built

Enrolment34/40
2,500 participants (target)
Site count25/25
303 sites
Country count15/15
19 countries
Planned duration7/10
Planned over about 23 months
Sponsor scale9/10
Novo Nordisk A/S has led 320 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks

Conditions

Obesity
Type 2 Diabetes

Eligibility

Eligibility
Sex	All
Ages	18 Years – No maximum
Healthy volunteers	No

Eligibility as written in the registry

Inclusion Criteria : * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * BMI≥ 35.0 kg/m\^2. * Participants without T2D: No history of T2D and HbA1c \< 6.5% (48 millimoles per mole (mmol/mol)) Participants with T2D: A history of T2D and HbA1c \< 10% (\< 86 mmol/mol). If a participant without a history of diabetes during the screening period receives an HbA1c result of 6.5% (48 mmol/mol) or higher, the investigator or the participant's healthcare provider must confirm the diagnosis of type 2 diabetes before the participant is randomised. Exclusion Criteria: * A self-reported change in body weight \> 5% within 90 days before screening, irrespective of medical records. * Use of any glucagon-like-peptide-1 receptor agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin analogues, including medication with amylin activity, within 6 months before screening.

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study type	Interventional
Phase	Phase 3
Allocation	Randomised
Intervention model	PARALLEL
Primary purpose	TREATMENT
Masking	QUADRUPLE (4)
Enrolment	2,500 participants sought

Sponsor and collaborators

Novo Nordisk A/S Sponsor

Arms and interventions

Cagrisema - dose level 1EXPERIMENTAL
Participants will receive CagriSema at dose level 1 once weekly subcutaneously during the treatment period for 72 weeks.
Cagrisema - dose level 2ACTIVE_COMPARATOR
Participants will receive CagriSema at dose level 2 once weekly subcutaneously during the treatment period for 72 weeks.
SemaglutideACTIVE_COMPARATOR
Participants will receive Semaglutide once weekly subcutaneously during the treatment period for 72 weeks.

Interventions

Drug Cagrisema
Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously.
Drug Semaglutide
Semaglutide will be administered subcutaneously.

Outcome measures

Primary outcome
Relative change in body weight
Measured as percentage (%).
Time frame From randomisation (week 0) to end of treatment (week 72)
Secondary outcome
Relative change in body weight
Measured as %.
Time frame From randomisation (week 0) to end of treatment (week 72)
Secondary outcome
Change in Body Mass Index (BMI)
Measured as kilograms per square metre (kg/m\^2).
Time frame From randomisation (week 0) to end of treatment (week 72)
Secondary outcome
Number of participants who achieve greater than or equal to (≥) 30% weight reduction
Measured as count of participants.
Time frame From randomisation (week 0) to end of treatment (week 72)
Secondary outcome
Number of participants who achieve ≥25% weight reduction
Measured as count of participants.
Time frame From randomisation (week 0) to end of treatment (week 72)
Secondary outcome
Number of participants who achieve greater ≥ 20% weight reduction
Measured as count of participants.
Time frame From randomisation (week 0) to end of treatment (week 72)
Secondary outcome
Change in waist circumference
Measured in centimetre (cm).
Time frame From randomisation (week 0) to end of treatment (week 72)
Secondary outcome
Mean change in body weight
Measured in kilograms (kg).
Time frame From randomisation (week 0) to end of treatment (week 72)
Secondary outcome
Number of participants who achieve a BMI less than (<) 30 kg/m^2
Measured as count of participants.
Time frame From randomisation (week 0) to end of treatment (week 72)
Secondary outcome
Number of participants who achieve BMI <27 kg/m^2
Measured as count of participants.
Time frame end of treatment (week 72)
Secondary outcome
Number of participants who achieve normal BMI, defined as 18.5 lesser than or equal to (≤) BMI < 25 kg/m^2
Measured as count of participants.
Time frame At end of treatment (week 72)
Secondary outcome
Number of participants who achieve a waist-to-height ratio < 0.53
Measured as count of participants.
Time frame At end of treatment (week 72)
Secondary outcome
Ratio to baseline : Total cholesterol
Measured in terms of ratio.
Time frame From baseline (week 0) to end of treatment (week 72)
Secondary outcome
Ratio to baseline : High density lipoprotein (HDL) cholesterol
Measured in terms of ratio.
Time frame From baseline (week 0) to end of treatment (week 72)
Secondary outcome
Ratio to baseline : Low density lipoprotein (LDL) cholesterol
Measured in terms of ratio.
Time frame From baseline (week 0) to end of treatment (week 72)
Secondary outcome
Ratio to baseline : Very low density lipoprotein ( VLDL) cholesterol
Measured in terms of ratio.
Time frame From baseline (week 0) to end of treatment (week 72)
Secondary outcome
Ratio to baseline : Triglycerides
Measured in terms of ratio.
Time frame From baseline (week 0) to end of treatment (week 72)
Secondary outcome
Ratio to baseline: Free fatty acids
Measured in terms of ratio.
Time frame From baseline (week 0) to end of treatment (week 72)
Secondary outcome
Ratio to baseline : Non-HDL cholesterol
Measured in terms of ratio.
Time frame From baseline (week 0) to end of treatment (week 72)
Secondary outcome
Change in Short-Form-36 Health Survey Version 2.0 (SF-36v2) physical Function
Measured as score on a scale. The SF-36v2 acute measures health-related quality of life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 United States general population has a mean of 50 and a standard deviation of 10. Physical functioning score ranges from 19.0-57.6, with higher scores indicating better functional health and well-being.
Time frame From randomisation (week 0) to end of treatment (week 72)
Secondary outcome
Change in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) physical function
Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Physical function score ranges from 0 to 100, with higher scores indicating better levels of functioning.
Time frame From randomisation (week 0) to end of treatment (week 72)
Secondary outcome
Change in glycated haemoglobin (HbA1c)
Measured in %-points.
Time frame From randomisation (week 0) to end of treatment (week 72)
Secondary outcome
Number of participants who achieve HbA1c <6.5%
Measured as count of participants.
Time frame At end of treatment (week 72)
Secondary outcome
Number of participants who achieve normal HbA1c <5.7%
Measured as count of participants.
Time frame At end of treatment (week 72)
Secondary outcome
Number of treatment-emergent adverse events (TEAEs)
Measured in number of events.
Time frame From randomisation (week 0) to end of study (week 80)
Secondary outcome
Number of treatment-emergent serious adverse events (TESAEs)
Measured in number of events.
Time frame From randomisation (week 0) to end of study (week 80)

Dates

Dates
Start date	May 21, 2026 (actual)
Primary completion	February 23, 2028 (estimated)
Completion	April 19, 2028 (estimated)
First posted	May 4, 2026 (actual)
Last updated	August 31, 2026
Results posted	Not stated in the registry record
Status last verified	August 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

162 sites are recruiting

Argentina

Argentina
Facility	City	State or region	Status
OMI- Organización Médica de Investigación	Buenos Aires		Recruiting
Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli	Buenos Aires		Recruiting
Hospital Sirio Libanes	Buenos Aires		Recruiting
Kynet Recoleta	Buenos Aires		Recruiting
CEMEDIC	CABA	Buenos Aires	Recruiting
CEDIC Centro de Investigación Clínica	CABA		Not yet recruiting
CIPREC Arenales	CABA		Recruiting
Centro Médico Viamonte SRL	CABA		Recruiting
Centro de Investigaciones Metabólicas	Capital Federal	Buenos Aires	Recruiting
CICEMO- Consultorio (Av Directorio)	Ciudad Autónoma de Buenos Aires	Buenos Aires	Recruiting
Centro Médico Arsema	Ciudad Autónoma de Buenos Aires	Buenos Aires	Recruiting
Instituto Centenario	Ciudad de Buenos Aires		Recruiting
Centro de Investigación C.I.C.E 9 de Julio - Sanatorio 9 de Julio	San Miguel de Tucumán	Tucumán Province	Recruiting
CEDIR - Centro de diagnóstico y rehabilitación Santa Fe	Santa Fe		Recruiting
Sanatorio Norte	Santiago del Estero		Recruiting

Australia

Australia
Facility	City	State or region	Status
University of Sunshine Coast - Vitality Village	Birtinya	Queensland	Recruiting
Emeritus Research Melbourne	Camberwell	Victoria	Recruiting
Sydney Clinical Trials	Campbelltown	New South Wales	Recruiting
Gosford Renal Research	Gosford	New South Wales	Recruiting
Sydney Cardiometabolic Centre	Liverpool	New South Wales	Recruiting
Hunter Diabetes Centre	Merewether	New South Wales	Recruiting
University of Sunshine Coast - South Brisbane	South Brisbane	Queensland	Recruiting

Austria

Austria
Facility	City	Status
Medical University of Graz	Graz	Recruiting
Ordination Winhofer-Stöckl	Mattersburg	Recruiting
Fließer-Görzer [Ordination]	Saint Stefan	Recruiting
Universitätsklinikum AKH Wien	Vienna	Recruiting
Klinik Landstraße	Vienna	Recruiting
Ordination Dr. Günter Sokol	Vienna	Recruiting
Klinik Hietzing 3. Med. Abt.	Vienna	Recruiting
Itariu [Ordination]	Vienna	Recruiting

Belgium

Belgium
Facility	City	Status
Anima Research Center	Alken	Recruiting
Cliniques universitaires Saint-Luc	Brussels	Not yet recruiting
KORMONT	Kluisbergen	Recruiting
CHU Tivoli	La Louvière	Recruiting
MECLINAS	Mechelen	Recruiting
AZ Delta - Roeselare	Roeselare	Recruiting
KORMONT	Zwalm	Recruiting

Bulgaria

Bulgaria
Facility	City	Status
MC For Life EOOD	Burgas	Recruiting
MC Kazanlak EOOD	Kazanlak	Recruiting
Medical center Medi City 21 OOD	Kyustendil	Recruiting
OCSOMCE - Dr. Albena Dinkova EOOD	Pleven	Recruiting
AIPSMCEMDID - Dr. Georgi Levterov EOOD	Plovdiv	Recruiting
DCC Sveti Georgi EOOD	Plovdiv	Recruiting
Hipocrat 9 - Dr. Rumyana Boykova - Draganova - AISPEMD EOOD	Sofia	Recruiting
DCC XX - Sofia EOOD, Endocrinology	Sofia	Recruiting
MC Diamedical - 2013 OOD, Sofia	Sofia	Recruiting
Medical Centre Medical Arts Medico-dental centre	Sofia	Recruiting
DCC XXV Sofia EOOD, Endocrinology Consulting room	Sofia	Recruiting
UMHAT Prof. Dr. Stoyan Kirkovich AD	Stara Zagora	Recruiting
AIPSMC Dr. Evelina Zlatanova EOOD	Varna	Recruiting

253 further sites are listed in the registry record.

Study documents

No documents are linked in this registry record.

Changes over time

No changes have been recorded since we first ingested this record.

A change is recorded each time the sponsor updates the registry record. Status, dates, enrolment and sites appear here as they move.

Registry: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT07564414

Categories

Registered in 1 registry

Interested in this study?

How this study is set up

Summary

Conditions

Eligibility

Eligibility as written in the registry

Eligibility in plain statements

Study design

Sponsor and collaborators

Arms and interventions

Interventions

Outcome measures

Dates

Locations

Argentina

Australia

Austria

Belgium

Bulgaria

Study documents

Changes over time